



MAHINDRA & MAHINDRA

Automobiles

Healthy performance to continue; upgrade to BUY

- Automotive segment grew by ~14% YoY and tractor volume an encouraging 5% YoY in a dull quarter
- Gross margin gained ~181bps YoY to 26.5% (flat QoQ). EBITDA margin improved by 172bps/227bps YoY/QoQ to 15.2%
- Raise FY25 earnings by 3%, and introduce FY27 estimates. We upgrade to BUY, valuing MM at 20x 1Y forward P/E and higher TP of Rs 3,279

Steady topline growth in challenging quarter: MM's Q1FY25 revenue grew at a steady 12.8%/8.1% YoY/QoQ to Rs 271.3bn, driven by healthy volume uptick of 10.3%/14.1% YoY/QoQ. The automotive segment grew by ~14% YoY and tractor volume by an encouraging 5% YoY in a dull quarter. Despite the volume gains, the blended realisation/vehicle stayed positive at 2.3% YoY (-5.26% QoQ).

Uptick in EBITDA margin: Inventory-adjusted raw material cost stayed benign at 73.5% of sales from 75.3%/73.5% YoY/QoQ in Q1FY25, yielding nominal gross margin gains of ~181bps YoY to 26.5% (flat QoQ). EBITDA grew 27.2% YoY to Rs 41.2bn with margin gains of 172bps/227bps YoY/QoQ to 15.2%. Other expenses rose 14.5% YoY but decreased 17.7% QoQ to Rs 19.0bn.

FES segment gaining pace: MM's automotive business continued to dominate revenue with a 70% contribution in Q1FY25. However, the Farm Equipment segment (FES) saw a healthy uptick of 9.2% YoY as tractor volumes rose 4.7% YoY. The tractor volume may gain traction following normal monsoons.

Product pipeline remains strong: MM is planning to launch the new Thar Roxx in Q2FY25, besides the 3XO in 4QFY24 with encouraging initial bookings. MM has plans for a strong launch pipeline, including nine ICE SUVs (six new launches), seven LCVs (five ICE + two EVs) and seven EVs categorised as Born EV (BEV) spread over the next six years in two tranches (till FY27 and beyond till FY30).

Overall healthy performance, upgrade to BUY: We raise our FY25 estimates by 3% to factor in the healthy outlook from the FES and automotive segment following healthy monsoons and Q1 performance. We introduce FY27E earnings as we pencil in a 3Y EBITDA/PAT CAGR of 17%/13%. We expect FES to revive stronger, and the automotive segment to maintain strong momentum benefitting from MM's focus on driving volumes and market share. We continue to value MM's core business at 24x 1year P/E, a 10% premium to its long-term average (22x), resulting in a revised SOTPbased TP of Rs 3,279 (from Rs 3,210). This includes Rs 362/share as the value of subsidiaries. We upgrade MM to BUY from HOLD with an upside of 19%.

02 August 2024

Milind Raginwar research@bobcaps.in

Key changes

	Target	Rating		
	A	A		
Ticke	er/Price	MM IN/Rs 2,750		
Mark	et cap	US\$ 41.1bn		
Free	float	81%		
3M ADV		US\$ 112.7mn		
52wk high/low		Rs 3,014/Rs 1,416		
Prom	noter/FPI/DII	19%/37%/29%		

Source: NSE | Price as of 2 Aug 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E				
Total revenue (Rs mn)	9,87,634	11,24,218	12,77,570				
EBITDA (Rs mn)	1,26,662	1,56,309	1,81,302				
Adj. net profit (Rs mn)	1,07,178	1,19,982	1,42,360				
Adj. EPS (Rs)	89.5	100.1	118.8				
Consensus EPS (Rs)	89.5	99.6	115.1				
Adj. ROAE (%)	22.4	21.1	21.1				
Adj. P/E (x)	30.7	27.5	23.1				
EV/EBITDA (x)	26.9	21.6	18.8				
Adj. EPS growth (%)	63.7	11.9	18.7				
Source: Company, Bloomberg, BOBCAPS Research							

Stock performance



Source: NSE





Fig 1 – Earnings call highlights

Parameter	Q1FY25	Q4FY24	Our view
Market	MM's SUV revenue market share is up 130bps YoY, LCV share is up 160bps, tractor market share is up 180bps. Tractor volume was up as it gained market share to ~44.7%. Farm segment gained share domestically and LCV too gained market share in Q1FY25.	MM's SUV revenue market share grew 130bps YoY to 20.4% in FY24, LCV share by 350bps to 49.0%, and FES share 40bps to 41.6% in FY24 over FY23.	All the segments are looking at healthy volume delivery including automotive segment, FES. The revival in the LCV segment is very encouraging.
Order book	MM has seen good traction in markets where it has a presence with its new products especially following the response to XUV700 and Scorpio. The order book of certain models, however, is soft due to customers preferring lower waiting periods.	The company's order book as on 1 Feb 2024 stood at ~220 units, led by the Scorpio family (~86k open bookings), followed by the Thar series (~59k), XUV700 (~8k), Bolero (~10k). The newly launched XUV 3XO had bookings of 50k (launched in Jan'24). MM has a cancellation rate of ~10% per month.	The company's focus on lowering the wait period will bolster growth. The policy to revisit cancellations to clear old inventory stock faster for new product/series launches has been handy.
Electric Vehicle	MM has plans for a strong launch pipeline, including nine ICE SUVs (six new launches), seven LCVs (five ICE + two EV) and seven EVs categorised as Born EV (BEV) spread over the next six years in two tranches (till FY27 and beyond till FY30). MM will report BEV (Battery electric vehicle) margins separately from internal combustion engine (ICE) margins.	MM's EV penetration in the three-wheeler (3W) L5 category was ~11.0% in FY24. As per management, EV industry penetration in India is currently at 2% and the charging ecosystem remains weak and can be developed in a phased manner unlike in China where needs are assessed and worked on beforehand.	Aggressive programme of ~24 launches in the next six years with clear policy of focus on growth over earnings augurs well for MM.
FES	FES volumes rose 4.7%/64.2% YoY/QoQ to ~120.5k units in Q1FY25. Tractor volumes were up as MM gained market share besides 19.7% core tractor margin. MM expects good monsoons and higher spending by government in rural areas to be good drivers of growth for tractors.	FES volume fell 20% YoY to ~71k units in Q4FY24. MM continues to be the #2 player in rotavators with 20.3% market share in FY24. Management expects tractor industry volumes to improve significantly on predictions of normal monsoon in FY25. Products launched in North American markets: rotary tillers, loaders & backhoes.	Better monsoon predictions and actual monsoons have helped to turn the outlook in the FES segment in FY25
Margin	Margin expansion remained key theme for Q1FY25. Improved profitability drives significant 23% margin increase in automotive and agricultural sectors. This growth is underpinned by substantial PBIT enhancements of 9.5% and 18.5% respectively.	EBIT margin in the auto segment expanded 170bps YoY to 8.8% in Q4FY24, while FES saw margins maintained at 16.2% YoY in FY24 despite the inclusion of 0.2% one-time impact from Cricket World Cup sponsorship.	We expect MM's automotive segment to improve and FES weakness earlier to reverse. The low base effect will be handy.
Balance sheet information	Rs 50bn capex is primarily for the farm business which is regular capex. This is besides the capex earmarked for the EV and the automotive segments.	MM generated operating cash of Rs 150bn in FY24. It had capital expenditure of Rs 50bn. In addition to that, EV capex was Rs 30bn and debt repayment of Rs 35bn in FY24.	We see no concerns on the balance sheet given a prudent capital allocation policy.

Source: Company, BOBCAPS Research



(Rs mn)	Q1FY25	1QFY24	YoY (%)	4QFY24	QoQ (%)
Volume	3,32,042	3,01,147	10.3	2,91,109	14.1
Avg. Realisation per Vehicle	8,17,148	7,98,814	2.3	8,62,528	(5.3)
Net Revenues	2,71,328	2,40,561	12.8	2,51,090	8.1
Total Income (A)	2,71,328	2,40,561	12.8	2,51,090	8.1
Operating Expenses					
Raw materials consumed	1,99,394	1,81,149	10.1	1,84,462	8.1
Employee Expenses	11,753	10,447	12.5	11,112	5.8
Other Expenses	19,018	16,613	14.5	23,114	(17.7)
Total Expenditure (B)	2,30,166	2,08,209	10.5	2,18,689	5.2
EBITDA (A-B)	41,162	32,351	27.2	32,401	27.0
Other Income	2,576	9,699	(73.4)	5,474	(53.0)
Depreciation	9,146	8,281	10.4	9,770	(6.4
EBIT	34,591	33,769	2.4	28,105	23.1
Finance Costs	529	323	63.6	387	36.8
PBT after excep items	34,062	33,445	1.8	27,718	22.9
Tax expense	7,936	5,708	39.0	6,123	29.6
Reported PAT	26,126	27,737	(5.8)	21,595	21.0
Adjusted PAT	26,126	27,737	(5.8)	21,595	21.0
EPS (Rs)	21.0	22.3	(5.8)	16.4	28.2
Key Ratios (%)			(bps)		(bps)
Gross Margin	26.5	24.7	181	26.5	(2)
EBITDA Margin	15.2	13.4	172	12.9	227
EBIT Margin	12.7	14.0	(129)	11.2	156
PBT Margin	12.6	13.9	(135)	11.0	151
Tax Rate	23.3	17.1	623	22.1	121
Adj PAT Margin	9.6	11.5	(190)	8.6	103

Fig 2 – Quarterly performance (Standalone)

Source: Company, BOBCAPS Research



Valuation methodology

We raise our FY25 earnings estimates by 3% to factor in the healthy outlook from the FES and automotive segment following healthy monsoons and Q1 performance. We introduce FY27E earnings as we pencil in a 3Y EBITDA/PAT CAGR of 17%/13%. FES has indicated early signs of revival after predictions of actual normal/above normal monsoons and expected steady policy framework following the reinstatement of the existing government. Further, domestic agricultural market dynamics call for healthy tractor demand in the medium term.

We believe MM's aggressive growth plans will drive volume and market share in the automotive segment likely helping it to maintain strong momentum. MM has a strong focus on launch programmes in the automotive segment, including electric vehicles and in FES. Despite the strong capex for the automotive segment and FES, MM's capital allocation policy continues to imply less debt stress that will comfort the balance sheet health and keep the return ratios moving at a good pace.

Factoring in the same, we continue to value MM's core business at 24x P/E 1-year forward earnings, 10% premium to its long-term average (22x) resulting in a revised SOTP-based TP of Rs 3,279 (from Rs 3,210). We value MM's core business at Rs 2,848 and value its other businesses at Rs 362/share (Rs 319 earlier) given the healthy traction in these businesses. At our TP the stock offers 19% upside following the recent rationalisation in the valuations and, hence, we upgrade the stock to BUY from our earlier HOLD rating on the stock.

Fig 3 – Revised estimates

(Do mm)		New			Old			Change (%)	
(Rs mn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	11,24,218	12,77,570	14,32,670	11,32,898	12,84,925	NA	(0.8)	(0.6)	NA
EBITDA	1,56,309	1,81,302	2,02,987	1,59,261	1,89,763	NA	(1.9)	(4.5)	NA
Adj PAT	1,19,982	1,42,360	1,55,370	1,16,835	1,42,164	NA	2.7	0.1	NA
Adj EPS (Rs)	100.1	118.8	129.7	97.5	118.7	NA	2.7	0.1	NA

Source: BOBCAPS Research

Fig 4 – Key assumptions

Parameter	FY25E	FY26E	FY27E
Volume (units)	13,80,870	15,06,980	16,53,399
Revenue (Rs mn)	11,24,218	12,77,570	14,32,670
EBITDA (Rs mn)	1,56,309	1,81,302	2,02,987
EBITDA margin (%)	13.9	14.2	14.2
Adj. PAT (Rs mn)	1,19,982	1,42,360	1,55,370
EPS (Rs)	100.1	118.8	129.7

Source: Company, BOBCAPS Research

Fig 5 – Valuation summary

Business	Value (Rs/sh)	Valuation basis
Core Business	2,917	24x 1-year forward EPS
Subsidiaries	362	30% holding company discount
Total	3,279	

Source: BOBCAPS Research| Note: Valuations include partial FY27 earnings

MAHINDRA & MAHINDRA




Fig 6 – Peer comparison

Commony	Ticker Rating		Target Price	EPS (Rs)		ROE (%)	
Company	Ticker Rating	(Rs)	FY25E	FY26E	FY25E	FY26E	
Maruti Suzuki	MSIL IN	HOLD	13,305	471.3	526.9	16	15.8
Mahindra & Mahindra	MM IN	BUY	3,279	100.1	118.8	21.1	21.1
Tata Motors	TTMT IN	NOT RATED	-	66.5	80.1	25.9	24.4


Source: BOBCAPS Research

Fig 7 – P/E band: We value MM at 24x FY26E core business EPS



Source: Company, Bloomberg, BOBCAPS Research

Fig 8 – P/E 1Y fwd MM will continue to trade at premium



Key risks

Key downside risks to our estimates are:

- accelerated launches by competitors in the high-end automotive segment,
- slower-than-expected recovery in the farm equipment segment, and,
- commodity inflation sustaining for longer than expected in the high-end segment.



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	8,49,603	9,87,634	11,24,218	12,77,570	14,32,670
EBITDA	1,04,424	1,26,662	1,56,309	1,81,302	2,02,987
Depreciation	31,545	34,389	35,830	38,585	42,018
EBIT	98,331	1,36,217	1,53,958	1,81,752	2,00,633
Net interest inc./(exp.)	(2,728)	(1,388)	(2,082)	(2,118)	(2,330)
Other inc./(exp.)	25,452	43,944	33,479	39,035	39,664
Exceptional items	(14,295)	0	0	0	0
EBT	81,308	1,34,830	1,51,876	1,79,634	1,98,303
Income taxes	15,821	27,652	31,894	37,274	42,933
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	51,191	1,07,178	1,19,982	1,42,360	1,55,370
Adjustments	14,295	0	0	0	0
Adjusted net profit	65,486	1,07,178	1,19,982	1,42,360	1,55,370

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Accounts payables	1,81,336	1,99,990	2,34,512	2,65,607	2,98,053
Other current liabilities	59,797	60,729	42,187	49,443	62,217
Provisions	18,139	18,714	1,978	2,176	2,394
Debt funds	50,255	20,365	19,160	14,583	11,199
Other liabilities	0	0	0	0	0
Equity capital	5,991	5,996	5,996	5,996	5,996
Reserves & surplus	4,27,577	5,16,770	6,10,547	7,27,746	8,57,957
Shareholders' fund	4,33,567	5,22,766	6,16,543	7,33,743	8,63,953
Total liab. and equities	7,43,095	8,22,563	9,14,380	10,65,551	12,37,815
Cash and cash eq.	44,818	55,259	24,436	42,656	69,425
Accounts receivables	40,417	45,495	56,211	63,878	71,633
Inventories	88,814	95,048	1,12,422	1,34,145	1,46,849
Other current assets	1,15,271	1,29,520	1,79,875	2,04,411	2,29,227
Investments	2,70,871	2,99,954	3,42,488	3,95,098	4,87,786
Net fixed assets	1,88,106	1,94,378	1,98,549	2,19,964	2,27,945
CWIP	9,503	18,460	15,950	20,950	20,500
Intangible assets	0	0	0	0	0
Deferred tax assets, net	(14,703)	(15,551)	(15,551)	(15,551)	(15,551)
Other assets	0	0	0	0	0
Total assets	7,43,095	8,22,563	9,14,380	10,65,551	12,37,815

Cash Flows

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	74,304	90,834	41,050	1,24,413	1,55,558
Capital expenditures	(33,485)	(49,619)	(37,490)	(65,000)	(49,550)
Change in investments	(19,773)	(29,083)	(42,534)	(52,610)	(92,688)
Other investing cash flows	25,452	43,944	33,479	39,035	39,664
Cash flow from investing	(27,806)	(34,758)	(46,545)	(78,575)	(1,02,575)
Equities issued/Others	968	800	(794)	0	0
Debt raised/repaid	(17,080)	(29,891)	(1,204)	(4,577)	(3,384)
Interest expenses	(2,728)	(1,388)	(2,082)	(2,118)	(2,330)
Dividends paid	(19,469)	(25,160)	(25,160)	(25,160)	(25,160)
Other financing cash flows	8,963	7,229	(251)	0	0
Cash flow from financing	(29,347)	(48,410)	(29,491)	(31,856)	(30,874)
Chg in cash & cash eq.	17,152	7,666	(34,987)	13,983	22,109
Closing cash & cash eq.	44,818	55,259	24,436	42,656	69,425

Per Share Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27E
Reported EPS	54.7	89.5	100.1	118.8	129.7
Adjusted EPS	54.7	89.5	100.1	118.8	129.7
Dividend per share	16.3	21.0	21.0	21.0	21.0
Book value per share	361.9	436.3	514.6	612.4	721.1
	501.5	400.0	514.0	012.4	121.
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27E
EV/Sales	4.0	3.4	3.0	2.7	2.4
EV/EBITDA	32.4	26.9	21.6	18.8	16.8
Adjusted P/E	50.3	30.7	27.5	23.1	21.2
P/BV	7.6	6.3	5.3	4.5	3.8
					0.0
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27E
Tax burden (Net profit/PBT)	63.0	79.5	79.0	79.3	78.4
Interest burden (PBT/EBIT)	82.7	99.0	98.6	98.8	98.8
EBIT margin (EBIT/Revenue)	11.6	13.8	13.7	14.2	14.(
Asset turnover (Rev./Avg TA)	180.6	192.3	190.7	184.6	176.5
Leverage (Avg TA/Avg Equity)	1.1	1.1	1.0	1.0	1.0
Adjusted ROAE	12.4	22.4	21.1	21.1	19.4
Ratio Analysis					
Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27E
YoY growth (%)					
Revenue	47.9	16.2	13.8	13.6	12.1
EBITDA	51.4	21.3	23.4	16.0	12.0
Adjusted EPS	37.6	63.7	11.9	18.7	9.1
Profitability & Return ratios (%)					
EBITDA margin	12.3	12.8	13.9	14.2	14.2
EBIT margin	11.6	13.8	13.7	14.2	14.0
Adjusted profit margin	7.7	10.9	10.7	11.1	10.8
Adjusted ROAE	15.9	22.4	21.1	21.1	19.4
ROCE	16.9	21.0	20.6	20.8	19.3
Working capital days (days)					
Receivables	15	16	17	17	17
Inventory	32	34	34	35	36
Payables	90	94	95	96	96
Ratios (x)					
Gross asset turnover	0.5	0.4	0.4	0.4	0.4
Current ratio	1.1	1.2	1.3	1.4	1.4

 Adjusted debt/equity
 0.1
 0.0

 Source: Company, BOBCAPS Research | Note: TA = Total Assets

0.0

0.0

0.0



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): MAHINDRA & MAHINDRA (MM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

MAHINDRA & MAHINDRA



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.